Machine learnINg for the rElapse Risk eValuation in Acute Biliary Pancreatitis.
Launched by UNIVERSITY OF CAGLIARI · Nov 7, 2023
Trial Information
Current as of August 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The MINERVA clinical trial is studying how to better predict the risk of hospital readmission for patients with mild biliary acute pancreatitis, which is a condition often caused by gallstones. The goal is to create a simple scoring system, called the MINERVA score, using advanced technology known as machine learning. This score will help doctors determine the best treatment options for patients who have been admitted to the hospital but did not have surgery during their stay. By analyzing easily collected information from many patients, researchers aim to make this score available to healthcare providers worldwide, improving patient care.
To participate in the trial, individuals need to be adults (18 years or older) diagnosed with mild biliary acute pancreatitis and not have undergone any related surgeries during their hospital stay. Unfortunately, those with more severe cases of pancreatitis or other complications, as well as pregnant women, are not eligible. Participants will be part of a study that aims to validate the MINERVA score, which will be freely accessible online for doctors to use in their everyday practice. This means that if you take part, you could contribute to a tool that helps improve treatment for future patients with similar conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients (≥ 18 years old)
- • Clinical diagnosis of mild biliary acute pancreatitis (according to the Revised Atlanta Classification)
- • Not submitted to cholecystectomy or ERCP/ES (Endoscopic Retrograde CholangioPancreatography/Endoscopic Sphyncterotomy) during the same hospital admission
- Exclusion Criteria:
- • Acute pancreatitis of etiology other than gallstones;
- • Moderately-severe pancreatitis;
- • Severe pancreatitis;
- • Presence of pancreatic necrosis;
- • Pregnant patients;
- • Patients not able to sign the informed consent to take part in the study.
About University Of Cagliari
The University of Cagliari is a prominent academic institution located in Sardinia, Italy, renowned for its commitment to advancing medical research and education. With a strong emphasis on innovative clinical trials, the university leverages its interdisciplinary expertise and state-of-the-art facilities to drive advancements in healthcare. The institution collaborates with a network of researchers, clinicians, and industry partners to facilitate cutting-edge studies aimed at improving patient outcomes and addressing critical health challenges. Through its rigorous scientific approach and dedication to ethical research practices, the University of Cagliari plays a pivotal role in contributing to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cagliari, Ca, Italy
Patients applied
Trial Officials
Mauro Podda, MD
Study Chair
University of Cagliari, Department of Surgical Science
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported